Health In Tech, Inc. Class A Common Stock (HIT) Stock Forecast & Price Target
Health In Tech, Inc. Class A Common Stock · NASDAQ
$0.94-0.04 (-4.42%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Health In Tech, Inc. Class A Common Stock, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $3.00 to $4.00, so the covering firms are broadly aligned. The average target of $3.50 sits 274% above the current $0.94. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.03 next quarter toward $0.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Health In Tech, Inc. Class A Common Stock.
As of Sep, 2 of 2 firms rate HIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.03
Range $-0.03 – $-0.02 · 2 analysts · +150% YoY
Next period, 2 analysts expect Health In Tech, Inc. Class A Common Stock to earn $-0.03 a share (range $-0.03 – $-0.02), versus $-0.01 a year earlier. Full-year consensus is $-0.11, growing to $0.04 the year after.
REVENUE · NEXT QUARTER
$14.4M
Range $12.4M – $17.4M · 2 analysts · +91% YoY
Revenue is expected to reach $14.4M (range $12.4M – $17.4M), +91.2% year-over-year. Full-year consensus is $41.2M, rising to $71.2M next year.
Top analysts covering Health In Tech, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HIT.
#1
George Sutton
Craig-Hallum · Rank #139
Buy
$4.00+327.0% to target
Overall win rate
35%
+ Follow
#2
Allen Klee
Maxim Group · Rank #448
Buy
$3.00+220.3% to target
Overall win rate
18%
+ Follow
HIT stock forecast FAQ
What is HIT's average 12-month price target?+
The 2 analysts with a live target average $3.50 for Health In Tech, Inc. Class A Common Stock over the next 12 months, ranging from a $4.00 high to a $3.00 low.
Is HIT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HIT?+
The Street-high target is $4.00 (Craig-Hallum), and the Street-low is $3.00 (Maxim Group). The average of all 2 active targets is $3.50.
How many Wall Street analysts cover HIT?+
2 analysts have an active rating on Health In Tech, Inc. Class A Common Stock, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering HIT?+
Among analysts who currently cover HIT, George Sutton of Craig-Hallum has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $4.00 target.
What is Health In Tech, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.03 per share (range $-0.03 – $-0.02) across 2 analysts. Full-year EPS is projected at $-0.11, rising to $0.04 the following year.
How much revenue is Health In Tech, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $14.4M (range $12.4M – $17.4M). Full-year revenue is projected at $41.2M, growing to $71.2M next year.
Have analysts been upgrading or downgrading HIT lately?+
As of Sep, 2 of 2 firms rate HIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
